Global Complement Inhibitors Market is poised to witness trends by technological advances

The complement system plays a major role in innate and adaptive immunity. Complement inhibitors help reduce excessive or uncontrolled activation of the complement system in various immune-mediated and inflammatory conditions. Eculizumab was the first approved complement inhibitor drug, indicated for atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). More complement inhibitor products are under development for conditions like myocardial ischemia-reperfusion injury, transplantation, autoimmune diseases and neurodegenerative disorders.

The Global Complement Inhibitors Market is estimated to be valued at USD 85.10 Billion in 2024 and is expected to reach USD 236.11 Billion by 2031, growing at a compound annual growth rate (CAGR) of 15.7% from 2024 to 2031.

Key Takeaways

Key players operating in the Global Complement Inhibitors market are Amgen, Apellis Pharmaceuticals, Novartis, Alexion Pharmaceuticals, F. Hoffmann-La Roche Ltd.

The growing demand for Global Complement Inhibitors Market is mainly driven by increasing prevalence of complement-mediated diseases and shortage of organ donations leading to high demand for transplant procedures. According to WHO, around 7.6 million people suffer from stroke annually worldwide with about 6.7 million deaths from stroke each year making it a leading cause of death and disability.

Major pharmaceutical companies are investing in clinical research to develop new complement inhibitor drugs and expand their market presence globally. For instance, Apellis Pharmaceuticals’ peptide-Fc fusion protein inhibitor for geographic atrophy, intravitreal pegcetacoplan is under review with the FDA for approval with a decision expected in November 2022.

Market Key Trends

One of the key trends in the complement inhibitors market is development of oral formulations. Currently available inhibitors require intravenous administration limiting their use in chronic conditions requiring long-term treatment. Oral formulations offer advantages like ease of administration, reduced healthcare costs and improved patient compliance. Companies are investing in developing oral or convenient formulations of existing antibodies as well as new candidates from novel drug classes. This is expected to boost the adoption of complement inhibitors for chronic autoimmune and inflammatory conditions in the coming years.

Porter's Analysis

Threat of new entrants: The threat of new entrants in complementary inhibitors market is low as it requires huge capital investment, technology and also long approval process by regulatory bodies to enter the market.

Bargaining power of buyers: The bargaining power of buyers is moderate in this market as the products are differentiated and switching to alternatives requires doctors prescription and approval, so buyers cannot threaten price easily.

Bargaining power of suppliers: The bargaining power of suppliers is moderate in this market as there are many suppliers for active ingredients and other materials required for manufacturing complementary inhibitors however the switching cost for suppliers is low.

Threat of new substitutes: There is low threat of substitution in this market as the drugs have been approved for specific disease conditions and new substitutes require similar approval process to be accepted as replacement.

Competitive rivalry: The competitive rivalry is high among existing players to maintain their market share and gain leadership through continuous innovations.

Geographical Regions:

North America region currently holds the major share in the global complementary inhibitors market in terms of value owing to developed healthcare infrastructure and availability of advanced treatments.

Asia Pacific region is expected to witness the highest growth during the forecast period due to rising healthcare expenditure, growing incidences of target disease conditions and increasing penetration of new treatments in emerging countries like China and India.

Get this Report in Japanese Language: 世界の補体阻害剤市場

Get this Report in Korean Language: 글로벌 보체 억제제 시장

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)